Cargando…

Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis

BACKGROUND: To compare the efficacy and toxicity of irinotecan-based chemotherapy (IBC) and non-irinotecan-based chemotherapy (NIBC) as first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC). METHODS: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), ab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xue-Qin, Li, Chong-Yi, Xu, Ming-Fang, Zhao, Hong, Wang, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682247/ https://www.ncbi.nlm.nih.gov/pubmed/26673747 http://dx.doi.org/10.1186/s12885-015-1978-2

Ejemplares similares

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
por: Wachters, F M, et al.
Publicado: (2005)

Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?
por: Clements, Karen M., et al.
Publicado: (2010)

Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer
por: Fujita, A, et al.
Publicado: (2003)

Glasgow Prognostic Score in Patients Receiving Chemotherapy for Non-small-cell Lung Cancer in Stages IIIb and IV
por: Umihanic, Sefika, et al.
Publicado: (2014)

The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
por: Wang, Yuan, et al.
Publicado: (2017)

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
por: Zheng, Liang, et al.
Publicado: (2023)

A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus
por: Bang, Sun-Hwi, et al.
Publicado: (2012)

Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2015)

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry
por: Brat, Kristian, et al.
Publicado: (2020)

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer
por: Kroeber, Vinzenz, et al.
Publicado: (2014)

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2018)

Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
por: Shi, Sheng-Bin, et al.
Publicado: (2013)

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
por: Camidge, D. Ross, et al.
Publicado: (2014)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
por: OZKAYA, SEVKET, et al.
Publicado: (2012)

Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy
por: Zhao, Kewei, et al.
Publicado: (2021)

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study
por: Aktas, Gokmen, et al.
Publicado: (2016)

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
por: Boni, C, et al.
Publicado: (2012)

In vivo evaluation of an innovative synbiotics on stage IIIb-IV chronic kidney disease patients
por: Vacca, Mirco, et al.
Publicado: (2023)

Surgery for stage IIB–IIIB small cell lung cancer
por: Huang, Zhida, et al.
Publicado: (2023)

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
por: Zhou, Qing, et al.
Publicado: (2017)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
por: Fukuda, Akito, et al.
Publicado: (2022)

A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
por: Liu, Qing, et al.
Publicado: (2022)

Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer
por: Gupta, Digant, et al.
Publicado: (2009)

Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer
por: Zhao, Lei, et al.
Publicado: (2017)

Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations
por: Li, Xing, et al.
Publicado: (2019)

A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer
por: Sun, Manqiang, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China
por: Zhu, Chen, et al.
Publicado: (2021)

Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
por: Bakker, M., et al.
Publicado: (1995)

Comparison of Neoadjuvant Intraarterial Chemotherapy Versus Concurrent Chemoradiotherapy in Patients With Stage IIIB Uterine Cervical Cancer
por: Kawaguchi, Ryuji, et al.
Publicado: (2013)

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
por: Popa, Xitlally, et al.
Publicado: (2020)

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy
por: Catalano, V, et al.
Publicado: (2009)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients
por: Uprety, Dipesh, et al.
Publicado: (2018)

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
por: Shen, Dijian, et al.
Publicado: (2021)

Compound Kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A protocol for meta-analysis of randomized clinical trials following the PRISMA guidelines
por: Chen, Hongwei, et al.
Publicado: (2019)

Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non–Small Cell Lung Cancer Treated With First-Line Therapy
por: Ma, Xinran, et al.
Publicado: (2022)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery
por: Nasu, Kaei, et al.
Publicado: (2011)

Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer
por: Wang, Deqiang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5qc21vndkjhuvp8nip4nh2igb9